Autism spectrum disorders (ASDs) are collectively the most commonly diagnosed pediatric neurodevelopmental condition. ASDs include autism, pervasive developmental disorder-not otherwise specified (PDD-NOS), Rett syndrome and Asperger disorder. ASD is characterized by impaired communication and social interaction and may involve developmental delays and seizure disorders. Recent parent-reported diagnosis of ASD in the United States put it at higher levels (1:91) than previously thought, with its diagnosis in boys occurring 4 to 5 times more frequently than in girls (1:58).1 CDC estimates are currently 1:110;1 up from 1:150 in 2007.2 Annual medical expenditures for those affected are generally four to six times greater than for those without ASD.1 While twin studies demonstrate that genetics play a significant role in ASD, the impact of environment should not be underestimated, given the approximate 20-fold increase in incidence over the last 20 years.3
CDC.Prevalence of Autism Spectrum Disorders — Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2002. MMWR [http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5601a2.htm. Accessed 07/17/07.
3.
NewschafferCJ, CroenLA, DanielsJThe epidemiology of autism spectrum disorders.Annu Rev Public Health.2007; 28: 235–58.
4.
RimlandB, BakerSM. Brief report: alternative approaches to the development of effective treatments for autism.J Autism Dev Disord.Apr1996; 26(2): 237–41.
5.
O'HaraNH, SzakacsGM. The recovery of a child with autism spectrum disorder through biomedical interventions.Altern Ther Health Med.Nov-Dec2008; 14(6): 42–4.
6.
FrankLampe, SnyderS. Sidney MacDonald Baker, MD: taking a biomedical approach to autism treatment.Altern Ther Health Med.Nov-Dec2008; 14(6): 60–9.
7.
DethR, MuratoreC, BenzecryJ, Power-CharnitskyVA, WalyM. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis.Neurotoxicology.Jan2008; 29(1): 190–201.
8.
VojdaniA, O'BryanT, GreenJAImmune response to dietary proteins, gliadin and cerebellar peptides in children with autism.Nutr Neurosci.Jun2004; 7(3): 151–61.
9.
JamesSJ, CutlerP, MelnykSMetabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism.Am J Clin Nutr.Dec2004; 80(6): 1611–7.
10.
PolingJS, FryeRE, ShoffnerJ, ZimmermanAW. Developmental regression and mitochondrial dysfunction in a child with autism.J Child Neurol.Feb2006; 21(2): 170–2.
11.
KiddPM. Autism, an extreme challenge to integrative medicine. Part 2: medical management.Altern Med Rev.Dec2002; 7(6): 472–99.
12.
BischoffSC, GrabowskyJ, MannsMP. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls.Dig Dis Sci.Feb1997; 42(2): 394–403.
13.
JyonouchiH, GengL, RubyA, ReddyC, Zimmerman-BierB. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders.J Pediatr.May2005; 146(5): 605–10.
JamesSJ, MelnykS, JerniganSMetabolic endophenotype and related genotypes are associated with oxidative stress in children with autism.Am J Med Genet B Neuropsychiatr Genet. Dec 5 2006; 141(8): 947–56.
17.
WilliamsMT, SimonetL. In vivo suppression of stearyl CoA desaturase activity by griseofulvin: evidence against the involvement of lipid peroxidation.Toxicol Appl Pharmacol.Dec1988; 96(3): 541–9.
18.
WilliamsTA, MarsAE, BuyskeSGRisk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype.Arch Pediatr Adolesc Med.Apr2007; 161(4): 356–61.
19.
WakefieldAJ, PulestonJM, MontgomerySM, AnthonyA, O'LearyJJ, MurchSH. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands.Aliment Pharmacol Ther.Apr2002; 16(4): 663–74.
20.
BlaylockRL. A possible central mechanism in autism spectrum disorders, part 1.Altern Ther Health Med.Nov-Dec2008; 14(6): 46–53.
21.
MegsonMN. Is autism a G-alpha protein defect reversible with natural vitamin A?Med Hypotheses. Jun 2000; 54(6): 979–83.
22.
FrissoraCL, CashBD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome.Aliment Pharmacol Ther. Jun 1 2007; 25(11): 1271–81.
23.
FumiAL, TrexlerK. Rifaximin treatment for symptoms of irritable bowel syndrome.Ann Pharmacother.Mar2008; 42(3): 408–12.
24.
MajewskiM, ReddymasuSC, SostarichS, ForanP, McCallumRW. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.Am J Med Sci.May2007; 333(5): 266–70.
25.
JawharaS, PoulainD. Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis.Med Mycol.Dec2007; 45(8): 691–700.
26.
PhamM, LembergDA, DayAS. Probiotics: sorting the evidence from the myths.Med J Aust. Mar 3 2008; 188(5): 304–8.
27.
HaasRH. Autism and mitochondrial disease.Dev Disabil Res Rev. Jun;16(2):144–153.
28.
KiddPM. Autism, an extreme challenge to integrative medicine. Part: 1: The knowledge base.Altern Med Rev.Aug2002; 7(4): 292–316.
29.
KiddPM. Bipolar disorder and cell membrane dysfunction. Progress toward integrative management.Altern Med Rev.Jun2004; 9(2): 107–35.
30.
WakefieldAJ, MurchSH, AnthonyAIleal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.Lancet.1998; 351(9103): 637–41.
31.
Retraction-Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.Lancet. Feb 6;375(9713):445.
32.
WakefieldAJ, MurchSH, AnthonyAIleal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.Lancet. Feb 28 1998; 351(9103): 637–41.
33.
UribarriJ, OhMS, CarrollHJ. D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms.Medicine (Baltimore).Mar1998; 77(2): 73–82.
GoodwinBL, RuthvenCR, SandlerM. Gut flora and the origin of some urinary aromatic phenolic compounds.Biochem Pharmacol. Jun 15 1994; 47(12): 2294–7.
36.
TischendorfFW, BrattigNW, LintzelMEosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis.Trop Med Int Health.Dec2000; 5(12): 898–905.
37.
ArvolaT, MoilanenE, VuentoR, IsolauriE. Weaning to hypoallergenic formula improves gut barrier function in breast-fed infants with atopic eczema.J Pediatr Gastroenterol Nutr.Jan2004; 38(1): 92–6.
38.
Berni CananiR, RapacciuoloL, RomanoMTDiagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice.Dig Liver Dis.Jul2004; 36(7): 467–70.
39.
CaldariniMI, PonsS, D'AgostinoDAbnormal fecal flora in a patient with short bowel syndrome. An in vitro study on effect of pH on D-lactic acid production.Dig Dis Sci.Aug1996; 41(8): 1649–52.
40.
BullG, ShattockP, WhiteleyPIndolyl-3-acryloylglycine (IAG) is a putative diagnostic urinary marker for autism spectrum disorders.Med Sci Monit.Oct2003; 9(10): CR422-5.
41.
WrightB, BrzozowskiAM, CalvertEIs the presence of urinary indolyl-3-acryloylglycine associated with autism spectrum disorder?Dev Med Child Neurol. Mar 2005; 47(3): 190–2.
42.
AshwoodP, AnthonyA, TorrenteF, WakefieldAJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10.J Clin Immunol.Nov2004; 24(6): 664–73.
43.
PavoneL, FiumaraA, BottaroG, MazzoneD, ColemanM. Autism and celiac disease: failure to validate the hypothesis that a link might exist.Biol Psychiatry. Jul 1 1997; 42(1): 72–5.
44.
WhiteleyP, HaracoposD, KnivsbergAMThe ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders.Nutr Neurosci.Apr2010; 13(2): 87–100.
45.
VillaltaD, AlessioMG, TampoiaMDiagnostic accuracy of IgA anti-tissue transglutaminase antibody assays in celiac disease patients with selective IgA deficiency.Ann NY Acad Sci. Aug 2007; 1109: 212–20.
46.
AtkinsonW, SheldonTA, ShaathN, WhorwellPJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial.Gut.Oct2004; 53(10): 1459–64.
47.
MacdonaldTT, MonteleoneG. Immunity, inflammation, and allergy in the gut.Science. Mar 25 2005; 307(5717): 1920–1925.
48.
AmmingerGP, BergerGE, SchaferMR, KlierC, FriedrichMH, FeuchtM. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study.Biol Psychiatry. Feb 15 2007; 61(4): 551–3.
49.
JohnsonSM, HollanderE. Evidence that eicosapentaenoic acid is effective in treating autism.J Clin Psychiatry.Jul2003; 64(7): 848–9.
50.
BurrowsCJ, MullerJG, KornyushynaOStructure and potential mutagen-icity of new hydantoin products from guanosine and 8-oxo-7,8-dihydroguanine oxidation by transition metals.Environmental health perspectives.Oct2002; 110 Suppl 5:713–7.
51.
DethR, MuratoreC, BenzecryJ, Power-CharnitskyVA, WalyM. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis.Neurotoxicology. Oct 13 2007.
52.
JacksonAA, BadalooAV, ForresterT, HibbertJM, PersaudC. Urinary excretion of 5-oxoproline (pyroglutamic aciduria) as an index of glycine insufficiency in normal man.Br J Nutr.Sep1987; 58(2): 207–14.
GregusZ, WhiteC, HowellS, KlaassenCD. Effect of glutathione depletion on sulfate activation and sulfate ester formation in rats.Biochem Pharmacol. Nov 15 1988; 37(22): 4307–12.
55.
RossignolDA, FryeRE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis.Mol Psychiatry. Jan 25 2011.
56.
CorreiaC, CoutinhoAM, DiogoLBrief report High frequency of biochemical markers for mitochondrial dysfunction in autism: no association with the mitochondrial aspartate/glutamate carrier SLC25A12 gene.J Autism Dev Disord.Nov2006; 36(8): 1137–40.
57.
BresslerJP, OliviL, CheongJH, KimY, BannonaD. Divalent metal transporter 1 in lead and cadmium transportAnn NY Acad Sci. Mar 2004; 1012: 142–52.
58.
ChauhanA, ChauhanV, BrownWT, CohenI. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin-the antioxidant proteins.Life Sci. Oct 8 2004; 75(21): 2539–49.
59.
Mousain-BoscM, RocheM, PolgeA, Pradal-PratD, RapinJ, BaliJP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders.Magnes Res.Mar2006; 19(1): 46–52.
60.
McDonaldME, PaulJF. Timing of increased autistic disorder cumulative incidence.Environ Sci Technol. Mar 15 2010; 44(6): 2112–8.
61.
Hertz-PicciottoI, DelwicheL. The rise in autism and the role of age at diagnosis.Epidemiology (Cambridge, Mass.Jan2009; 20(1): 84–90.
62.
HerbertMR. Autism: A Brain Disorder, or a Disorder that Affects the Brain.Clinical Neuropsychiatry.2005; 2(6): 354–79.
63.
AmesBN. A role for supplements in optimizing health: the metabolic tune-up.Arch Biochem Biophys. Mar 1 2004; 423(1): 227–34.
64.
CurtisLT, PatelK. Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): a review.J Altern Complement Med. Jan-Feb 2008; 14(1): 79–85.
65.
HerbertMR. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders.Current Opin Neurol.Apr2010; 23(2): 103–10.
66.
HerbertMR. Autism: The centrality of active pathophysiology and the shift from static to chronic dynamic encephalopathy. In: ChauhanA, ChauhanV, BrownT, eds. Autism: oxidative stress, inflammation, and immune abnormalities.Boca Raton, FL: Taylor & Francis; 2009.
67.
ChauhanA, ChauhanV, BrownWT, CohenI. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin-the antioxidant proteins.Life Sci. Oct 8 2004; 75(21): 2539–49.
68.
HerbertMR. Learning from the autism catastrophe: key leverage points.Alternative therapies in health and medicine.Nov-Dec2008; 14(6): 28–30.
